REGENXBIO Inc (RGNX) Actualités

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific...

Form 8-K - Current report

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases PR...

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results...

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Feb. 25, 2025 ROCKVILLE...

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 PR Newswire ROCKVILLE...

Form 8-K - Current report

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111...

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]